ASX News
Neuren sees FDA greenlight for 3rd trial into children with Phelan-McDermid syndrome
Neuren has confirmed it's received "positive" FDA responses for its Phase III trial to treat children with Phelan-McDermid syndrome.
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
Latest Threads
| Tag | Subject | ||||||
|---|---|---|---|---|---|---|---|
| WEM | Ann: Month end units on issue | 04/10/24 | 0 | 69 | |||
|
|||||||
| WEM | Ann: Month end units on issue | 05/09/24 | 0 | 84 | |||
|
|||||||
| WEM | Ann: Annual Report to shareholders | 28/08/24 | 0 | 59 | |||
|
|||||||
| WEM | Ann: Month end units on issue | 16:49 | 0 | 90 | |||
|
|||||||
| WEM | Ann: Director Appointment/Resignation | 29/07/24 | 0 | 87 | |||
|
|||||||
| WEM | Ann: Primary Market Closure | 25/07/24 | 0 | 83 | |||
|
|||||||
| WEM | Ann: Primary Market Closure | 24/07/24 | 0 | 103 | |||
|
|||||||
| WEM | Ann: Month end units on issue | 04/07/24 | 0 | 88 | |||
|
|||||||
See All Discussions
Timeline
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
|
|
|
||||
| View More | |||||
